Study population
drug-refractory paroxysmal, atrial appendage occlusion, non-cardiac, hemorrhagic stroke, valvular abnormalities, atrial appendage thrombus, intracardiac thrombus, acute coronary syndrome, liver and kidney disease
HEMORRHAGIC STROKE, THYROID DISEASE, SEVERE LEFT VENTRICULAR HYPERTROPHY, HEMATOLOGICAL DISEASES, PERSISTENT ATRIAL FIBRILLATION, ELECTROLYTE DISORDER, BLEEDING TENDENCY, SECONDARY, INTRACARDIAC THROMBUS, ACUTE CORONARY SYNDROME
Patients scheduled for CB ablation of AF in the Department of Cardiac pacing in the first affiliated Hospital of Xinjiang Medical University from August 2021 to July 2022 were randomly divided into the standard group and the KODEX group. All patients understand the indications and risks of the operation before the operation, and sign the operation written consent form. And informed written consent has been obtained from all participants and/or their legal guardians. The same operator team performed CB ablation of AF on all 40 patients. The baseline characteristics of patients, procedure data were analyzed. Patients with previous ablation history, significant valvular abnormalities, and intracardiac thrombus were excluded from the study. Inclusion criteria: patients with paroxysmal AF or persistent AF whose duration is less than 12 months, according to the existing quality regimen, patients with AF need CB ablation: the main inclusion conditions are: (1) 18 years old ≤ age ≤ 85 years old; (2) symptomatic patients with drug-refractory paroxysmal or persistent atrial fibrillation; (3) patients who understand the purpose of the research, voluntarily participate in the research and sign the informed written consent are suitable. Exclusion criteria: those with any of the following criteria were excluded: (1) valvular AF or AF secondary to electrolyte disorders, thyroid disease, or other reversible non-cardiac causes; (2) previous history of left atrial ablation or surgery (including left atrial appendage occlusion); (3) left ventricular ejection fraction (LVEF) < 40%, or NYHA cardiac function grade III and IV or left atrial diameter ≥ 55 mm; (4) left atrial or left atrial appendage thrombus; (5) moderate to severe left ventricular hypertrophy (wall thickness > 1.5 cm); (6) patients with hemorrhagic stroke within 3 months; (7) patients with severe liver and kidney disease (ALT ≥ 3ULN or eGFR < 50 ml/min); (8) patients with obvious bleeding tendency and hematological diseases; (9) patients with acute coronary syndrome or patients who need stent implantation; (10) the participants have participated in clinical trials of other drugs or devices in the same period.